|
業務類別
|
-- |
|
業務概覽
|
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generatefuture cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales. |
| 公司地址
| 6 Rue Alain Bombard, Saint-Herblain, FRA, 44800 |
| 電話號碼
| +33 228073710 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.valneva.com |
| 員工數量
| 713 |
| Ms. Dipal Patel |
Chief Commercial Officer |
歐元 379.39K |
24/03/2025 |
| Mr. Vincent Dequenne |
Chief Operating Officer |
-- |
24/03/2025 |
| Mr. Franck Grimaud |
Chief Business Officer |
歐元 291.75K |
24/03/2025 |
| Ms. Petra Pesendorfer |
Chief People Officer |
-- |
24/03/2025 |
| Mr. Thomas Lingelbach |
Director, President and Chief Executive Officer |
歐元 573.20K |
24/03/2025 |
| Mr. Peter Buhler |
Chief Financial Officer |
歐元 410.97K |
24/03/2025 |
| Ms. Hanneke Schuitemaker |
Chief Scientific Officer |
-- |
24/03/2025 |
| Dr. Juan Carlos Jaramillo, M.D. |
Chief Medical Officer |
歐元 375.49K |
24/03/2025 |
| Ms. Kendra Wergin |
General Counsel and Corporate Secretary |
-- |
24/03/2025 |
|
|
| Ms. Mailys Ferrere |
Director |
24/03/2025 |
| Mr. James Connolly |
Independent Director |
24/03/2025 |
| Mr. James R. Sulat |
Vice Chairman of the Board |
24/03/2025 |
| Mr. Thomas Lingelbach |
Director, President and Chief Executive Officer |
24/03/2025 |
| Dr. Kathrin Jansen, PhD |
Director |
24/03/2025 |
| Ms. Anne-Marie Graffin |
Chairman of the Board |
24/03/2025 |
| Ms. Daniele Guyot-Caparros |
Independent Director |
24/03/2025 |
|
|
|
|
